BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 18765309)

  • 1. Current treatment options for Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström macroglobulinaemia.
    Fonseca R; Hayman S
    Br J Haematol; 2007 Sep; 138(6):700-20. PubMed ID: 17672883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waldenström macroglobulinemia: a review of therapy.
    Gertz MA
    Am J Hematol; 2005 Jun; 79(2):147-57. PubMed ID: 15929102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in Waldenström macroglobulinemia.
    Burwick N; Roccaro AM; Leleu X; Ghobrial IM
    Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How we treat Waldenström's macroglobulinemia.
    Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
    Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on therapeutic options in Waldenström macroglobulinemia.
    Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
    Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel treatment regimens for Waldenström's macroglobulinemia.
    García-Sanz R; Ocio EM
    Expert Rev Hematol; 2010 Jun; 3(3):339-50. PubMed ID: 21082984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM).
    Anagnostopoulos A; Giralt S
    Bone Marrow Transplant; 2002 Jun; 29(12):943-7. PubMed ID: 12098060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waldenstrom macroglobulinemia: prognosis and management.
    Oza A; Rajkumar SV
    Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
    J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia.
    Munshi NC; Barlogie B
    Semin Oncol; 2003 Apr; 30(2):282-5. PubMed ID: 12720153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waldenström macroglobulinemia.
    Kasi PM; Ansell SM; Gertz MA
    Clin Adv Hematol Oncol; 2015 Jan; 13(1):56-66. PubMed ID: 25679974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
    Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.